Should employers take a chance on Embarc to pay for gene therapy?
Should employers take a chance on Embarc to pay for gene therapy?
The promise of curing deadly diseases by administering a one-time therapy that rewrites a patient’s genetic code is no longer the stuff of science fiction. Yet this innovation comes with a steep price tag.
Zolgensma, approved for spinal muscular atrophy (SMA), has a list price of approximately $2.1 million. Other gene- and cell-based therapies coming to the market have launched at prices in the…
View On WordPress











